Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
- Resource Type
- Article
- Source
- In
The Lancet 1-7 April 2023 401(10382):1091-1102 - Subject
Primary Research Articles - Language
- ISSN
- 0140-6736